Brentuximab Vedotin and Pembrolizumab Trial for Metastatic Cancers Initiated
A new clinical trial is investigating the combination of brentuximab vedotin and pembrolizumab in patients with metastatic solid tumors.
Asset / Drug
Drug and asset intelligence for Seagen with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.